While there is no effective and clinically safe inhibitors of P-gp available to date (Robey et al., 2018; Leopoldo et al., 2019; Dong et al., 2020), the results of several clinical trials have shown that cancer patients could benefit from the co-administration of conventional anticancer agents with TKIs (Geyer et al., 2006; Moore et al., 2007; Yang et al., 2013; Cetin et al., 2014; Alemany et al., 2018). Here, PGP is linked to cancer.